Cue Biopharma
CUE
63 hedge funds and large institutions have $168M invested in Cue Biopharma in 2019 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 22 increasing their positions, 9 reducing their positions, and 6 closing their positions.
3,214% more capital inflows, than outflows
Capital inflows: $48.5M | Capital outflows: $1.46M
300% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 6
144% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 9
40% more funds holding
Funds holding: 45 → 63 (+18)
18.98% more ownership
Funds ownership: 26.93% → 45.91% (+19%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Avoro Capital Advisors
New York
|
+$19.6M |
| 2 |
Mangrove Partners
Greenwich,
Connecticut
|
+$6.3M |
| 3 |
Crestwood Advisors Group
Boston,
Massachusetts
|
+$2.83M |
| 4 |
Precept Management
Dallas,
Texas
|
+$1.78M |
| 5 |
BlackRock
New York
|
+$1.74M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sphera Funds Management
Tel Aviv,
Israel
|
-$422K |
| 2 |
HSBC Holdings
London,
United Kingdom
|
-$397K |
| 3 |
Millennium Management
New York
|
-$117K |
| 4 |
Citigroup
New York
|
-$108K |
| 5 |
PGM
Parian Global Management
Pound Ridge,
New York
|
-$93K |
CUE Hedge Fund Activity: Q4 2019 in Review
63 of the 5,094 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q4 2019, worth a combined $168M — up 227% from $51.3M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new CUE positions and 6 closed out — a net gain of 18 holders — while 22 added to existing stakes and 9 trimmed.
The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $19.6M. The largest seller was Sphera Funds Management, exiting entirely with an estimated $422K sold.
- 63 institutional investors held Cue Biopharma (CUE) as of Q4 2019, up from 45 in Q3 2019.
- Funds reported $168M of Cue Biopharma stock for Q4 2019, up 227% quarter-over-quarter.
- 24 funds opened new Cue Biopharma positions in Q4 2019 and 6 closed out, a net change of +18 holders.
- The largest Cue Biopharma buyer in Q4 2019 was Avoro Capital Advisors, an estimated $19.6M added.
- The largest Cue Biopharma seller in Q4 2019 was Sphera Funds Management, an estimated $422K sold.
Based on aggregated 13F filings for Q4 2019.